vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and BCB BANCORP INC (BCBP). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $20.0M, roughly 1.3× AGIOS PHARMACEUTICALS, INC.). BCB BANCORP INC runs the higher net margin — -49.7% vs -541.1%, a 491.4% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 13.1%). BCB BANCORP INC produced more free cash flow last quarter ($34.9M vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 1.8%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
AGIO vs BCBP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $26.2M |
| Net Profit | $-108.0M | $-12.0M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | -71.9% |
| Net Margin | -541.1% | -49.7% |
| Revenue YoY | 86.1% | 13.1% |
| Net Profit YoY | -11.9% | -467.6% |
| EPS (diluted) | $-1.86 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $26.2M | ||
| Q3 25 | $12.9M | $26.5M | ||
| Q2 25 | $12.5M | $25.2M | ||
| Q1 25 | $8.7M | $23.8M | ||
| Q4 24 | $10.7M | $23.1M | ||
| Q3 24 | $9.0M | $26.2M | ||
| Q2 24 | $8.6M | $20.4M | ||
| Q1 24 | $8.2M | $25.3M |
| Q4 25 | $-108.0M | $-12.0M | ||
| Q3 25 | $-103.4M | $4.3M | ||
| Q2 25 | $-112.0M | $3.6M | ||
| Q1 25 | $-89.3M | $-8.3M | ||
| Q4 24 | $-96.5M | $3.3M | ||
| Q3 24 | $947.9M | $6.7M | ||
| Q2 24 | $-96.1M | $2.8M | ||
| Q1 24 | $-81.5M | $5.9M |
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — | ||
| Q1 24 | 92.3% | — |
| Q4 25 | -608.9% | -71.9% | ||
| Q3 25 | -907.4% | 21.9% | ||
| Q2 25 | -1020.1% | 19.9% | ||
| Q1 25 | -1222.0% | -49.2% | ||
| Q4 24 | -1165.3% | 19.9% | ||
| Q3 24 | -1146.9% | 35.7% | ||
| Q2 24 | -1228.3% | 19.5% | ||
| Q1 24 | -1124.3% | 33.0% |
| Q4 25 | -541.1% | -49.7% | ||
| Q3 25 | -803.1% | 16.1% | ||
| Q2 25 | -899.4% | 14.2% | ||
| Q1 25 | -1023.3% | -35.0% | ||
| Q4 24 | -899.6% | 14.1% | ||
| Q3 24 | 10574.7% | 25.5% | ||
| Q2 24 | -1115.7% | 13.8% | ||
| Q1 24 | -995.8% | 23.2% |
| Q4 25 | $-1.86 | $-0.73 | ||
| Q3 25 | $-1.78 | $0.22 | ||
| Q2 25 | $-1.93 | $0.18 | ||
| Q1 25 | $-1.55 | $-0.51 | ||
| Q4 24 | $-1.44 | $0.17 | ||
| Q3 24 | $16.22 | $0.36 | ||
| Q2 24 | $-1.69 | $0.14 | ||
| Q1 24 | $-1.45 | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $304.3M |
| Total Assets | $1.3B | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | — | ||
| Q3 25 | $92.7M | — | ||
| Q2 25 | $80.9M | — | ||
| Q1 25 | $79.0M | — | ||
| Q4 24 | $76.2M | — | ||
| Q3 24 | $253.7M | — | ||
| Q2 24 | $84.5M | — | ||
| Q1 24 | $118.8M | — |
| Q4 25 | $1.2B | $304.3M | ||
| Q3 25 | $1.3B | $318.5M | ||
| Q2 25 | $1.4B | $315.7M | ||
| Q1 25 | $1.5B | $314.7M | ||
| Q4 24 | $1.5B | $323.9M | ||
| Q3 24 | $1.6B | $328.1M | ||
| Q2 24 | $660.5M | $320.7M | ||
| Q1 24 | $743.9M | $320.1M |
| Q4 25 | $1.3B | $3.3B | ||
| Q3 25 | $1.4B | $3.4B | ||
| Q2 25 | $1.5B | $3.4B | ||
| Q1 25 | $1.6B | $3.5B | ||
| Q4 24 | $1.7B | $3.6B | ||
| Q3 24 | $1.8B | $3.6B | ||
| Q2 24 | $773.1M | $3.8B | ||
| Q1 24 | $849.7M | $3.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $35.9M |
| Free Cash FlowOCF − Capex | $-97.3M | $34.9M |
| FCF MarginFCF / Revenue | -487.5% | 133.3% |
| Capex IntensityCapex / Revenue | 5.6% | 4.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $58.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $35.9M | ||
| Q3 25 | $-88.2M | $8.7M | ||
| Q2 25 | $-77.1M | $10.3M | ||
| Q1 25 | $-111.5M | $5.0M | ||
| Q4 24 | $-133.2M | $67.7M | ||
| Q3 24 | $-84.2M | $43.5M | ||
| Q2 24 | $-72.6M | $8.1M | ||
| Q1 24 | $-99.9M | $8.3M |
| Q4 25 | $-97.3M | $34.9M | ||
| Q3 25 | $-89.7M | $8.5M | ||
| Q2 25 | $-78.0M | $10.2M | ||
| Q1 25 | $-112.3M | $4.7M | ||
| Q4 24 | $-134.1M | $66.5M | ||
| Q3 24 | $-84.6M | $43.4M | ||
| Q2 24 | $-72.7M | $8.1M | ||
| Q1 24 | $-100.0M | $8.1M |
| Q4 25 | -487.5% | 133.3% | ||
| Q3 25 | -696.5% | 32.0% | ||
| Q2 25 | -626.2% | 40.4% | ||
| Q1 25 | -1286.4% | 19.8% | ||
| Q4 24 | -1250.1% | 287.5% | ||
| Q3 24 | -944.2% | 166.0% | ||
| Q2 24 | -844.4% | 39.6% | ||
| Q1 24 | -1221.2% | 32.3% |
| Q4 25 | 5.6% | 4.0% | ||
| Q3 25 | 12.1% | 1.1% | ||
| Q2 25 | 7.0% | 0.6% | ||
| Q1 25 | 8.8% | 1.2% | ||
| Q4 24 | 9.0% | 5.3% | ||
| Q3 24 | 4.7% | 0.3% | ||
| Q2 24 | 1.8% | 0.2% | ||
| Q1 24 | 1.7% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.05× | ||
| Q2 25 | — | 2.90× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 20.70× | ||
| Q3 24 | -0.09× | 6.53× | ||
| Q2 24 | — | 2.88× | ||
| Q1 24 | — | 1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
